Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Illustrative points system for the incremental-benefits variable

From: Which health technologies should be funded? A prioritization framework based explicitly on value for money

Dimensions Points (weights)
Lives saved, including ‘statistical’ lives (i.e. cure or reduced risk of death)  
 None (or not yet known) 0
 Few: 1-50 lives saved 0.091
 Some: 51-250 lives saved 0.192
 Many: 251-500 lives saved 0.268
 Very many: > 500 lives saved 0.343
Life-prolongation benefits – in terms of increase in life expectancy and its quality-of-life, and number of patients affected  
 None/Very small (or not yet known) 0
 Small benefits 0.053
 Medium benefits 0.152
 Large benefits 0.244
Quality-of-life gains – in terms of baseline QoL, size of QoL gains and duration, and number of patients affected  
 None/Very small (or not yet known) 0
 Small QoL gains 0.051
 Medium QoL gains 0.138
 Large QoL gains 0.217
If this technology were not to be funded …  
 Many/most patients will be able to pay for it themselves (privately) 0
 Many/most patients will get an alternative treatment (less effective) already funded by government 0.055
 Many/most patients will not receive any treatment for condition 0.108
Other important social or ethical benefits, e.g. targeted to children/minorities; reduces health gaps, etc  
 None/Very small (or not yet known) 0
 Yes 0.087
  1. Note: The bolded values represent the relative weights of the dimensions overall (i.e. the bolded values sum to unity).